Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
opioid |
| gptkbp:CASNumber |
120888-74-7
|
| gptkbp:criteria |
delta opioid receptor
|
| gptkbp:developedBy |
selective delta opioid receptor antagonist
|
| gptkbp:discoveredBy |
gptkb:Upjohn
|
| gptkbp:discoveredIn |
1980s
|
| gptkbp:hasInChIKey |
QJQYQJXOMNQJQJ-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C26H25NO3
|
| gptkbp:hasSMILES |
C1CC1CN2CCC34C5CC6=C7C(=C(C=C6O)O)O[C@@]7(CC[C@@H]3[C@@H]2C4)C5
|
| https://www.w3.org/2000/01/rdf-schema#label |
naltrindole
|
| gptkbp:IUPACName |
17-(cyclopropylmethyl)-6,7,8,14-tetrahydro-4,5α-epoxy-3,14β-dihydroxy-2,13α,5β-methano-morphinan
|
| gptkbp:legalStatus |
not approved for medical use
|
| gptkbp:molecularWeight |
399.48 g/mol
|
| gptkbp:PubChem_CID |
5486971
CHEMBL25416 |
| gptkbp:relatedTo |
gptkb:naloxone
gptkb:naltrexone |
| gptkbp:routeOfAdministration |
experimental
|
| gptkbp:studiedBy |
opioid receptor studies
|
| gptkbp:UNII |
6Q6X5A8H2E
|
| gptkbp:bfsParent |
gptkb:delta-opioid_receptor
|
| gptkbp:bfsLayer |
7
|